RESUMEN
Xanthine and hypoxanthine are intermediate metabolites of uric acid and a source of reactive oxidative species (ROS) by xanthine oxidoreductase (XOR), suggesting that facilitating their elimination is beneficial. Since they are reabsorbed in renal proximal tubules, we investigated their reabsorption mechanism by focusing on the renal uric acid transporters URAT1 and GLUT9, and examined the effect of clinically used URAT1 inhibitor on their renal clearance when their plasma concentration is increased by XOR inhibitor. Uptake study for [3H]xanthine and [3H]hypoxanthine was performed using URAT1- and GLUT9-expressing Xenopus oocytes. Transcellular transport study for [3H]xanthine was carried out using Madin-Darby canine kidney (MDCK)II cells co-expressing URAT1 and GLUT9. In in vivo pharmacokinetic study, renal clearance of xanthine was estimated based on plasma concentration and urinary recovery. Uptake by URAT1- and GLUT9-expressing oocytes demonstrated that xanthine is a substrate of URAT1 and GLUT9, while hypoxanthine is not. Transcellular transport of xanthine in MDCKII cells co-expressing URAT1 and GLUT9 was significantly higher than those in mock cells and cells expressing URAT1 or GLUT9 alone. Furthermore, dotinurad, a URAT1 inhibitor, increased renal clearance of xanthine in rats treated with topiroxostat to inhibit XOR. It was suggested that xanthine is reabsorbed in the same manner as uric acid through URAT1 and GLUT9, while hypoxanthine is not. Accordingly, it is expected that treatment with XOR and URAT1 inhibitors will effectively decrease purine pools in the body and prevent cell injury due to ROS generated during XOR-mediated reactions.
Asunto(s)
Proteínas de Transporte de Anión/metabolismo , Proteínas Facilitadoras del Transporte de la Glucosa/metabolismo , Proteínas de Transporte de Monosacáridos/metabolismo , Transportadores de Anión Orgánico/metabolismo , Proteínas de Transporte de Catión Orgánico/metabolismo , Xantina/farmacocinética , Animales , Proteínas de Transporte de Anión/antagonistas & inhibidores , Benzotiazoles/administración & dosificación , Perros , Proteínas Facilitadoras del Transporte de la Glucosa/genética , Túbulos Renales Proximales/efectos de los fármacos , Túbulos Renales Proximales/metabolismo , Células de Riñón Canino Madin Darby , Modelos Animales , Nitrilos/administración & dosificación , Oocitos , Transportadores de Anión Orgánico/genética , Proteínas de Transporte de Catión Orgánico/genética , Piridinas/administración & dosificación , Ratas , Ratas Wistar , Especies Reactivas de Oxígeno , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Eliminación Renal/efectos de los fármacos , Ácido Úrico/metabolismo , Xantina/sangre , Xantina/metabolismo , Xantina/orina , Xantina Deshidrogenasa/antagonistas & inhibidores , Xantina Deshidrogenasa/metabolismo , Xenopus laevisRESUMEN
INTRODUCTION: The suitability of novel positron emission tomography (PET) radioligands for quantitative in vivo imaging is affected by various physicochemical and pharmacological parameters. In this study, the combined effect of binding affinity, lipophilicity, protein binding and blood plasma level on cerebral pharmacokinetics and PET imaging characteristics of three xanthine-derived A1 adenosine receptor (A1AR) radioligands was investigated in rats. METHODS: A comparative evaluation of two novel cyclobutyl-substituted xanthine derivatives, 8-cyclobutyl-3-(3-[18F]fluoropropyl)-1-propylxanthine ([18F]CBX) and 3-(3-[18F]fluoropropyl)-8-(1-methylcyclobutyl)-1-propylxanthine ([18F]MCBX), with the reference A1AR radioligand 8-cyclopentyl-3-(3-[18F]fluoropropyl)-1-propylxanthine ([18F]CPFPX) was conducted. This evaluation included in vitro competition binding assays, in vitro autoradiography and in vivo PET imaging. Differences in cerebral pharmacokinetics and minimal scan duration required for quantification of cerebral distribution volume (VT) were assessed. RESULTS: Measured Ki values of non-labeled CBX, MCBX and CPFPX were 10.0 ± 0.52 nM, 3.3 ± 0.30 nM and 1.4 ± 0.15 nM, respectively (n = 3-4). In vitro autoradiographic binding patterns in rat brain were comparable between the radioligands, as well as the fraction of non-specific binding (1.0-1.9%). In vivo cerebral pharmacokinetics of the novel cyclobutyl-substituted xanthines differed considerably from that of [18F]CPFPX. Brain uptake and VT of [18F]CBX were substantially lower despite the higher concentration of radiotracer in plasma. [18F]MCBX showed comparable uptake and VT, but faster cerebral kinetics than [18F]CPFPX. However, the faster kinetics of [18F]MCBX did not enable the quantification of cerebral VT in a shorter scan time. CONCLUSIONS: The combined effect of individual physicochemical and pharmacological properties of a radiotracer on its PET imaging characteristics cannot be readily predicted. In vivo performance of the xanthine A1AR radioligands was mainly influenced by binding affinity; plasma concentrations and cerebral kinetics were of secondary importance.
Asunto(s)
Encéfalo/metabolismo , Tomografía de Emisión de Positrones , Receptor de Adenosina A1/metabolismo , Xantina/farmacocinética , Animales , Encéfalo/diagnóstico por imagen , Interacciones Hidrofóbicas e Hidrofílicas , Ligandos , Masculino , Ratas , Ratas Sprague-Dawley , Xantina/sangre , Xantina/química , Xantina/metabolismoRESUMEN
Adenosine induces bronchial hyperresponsiveness and inflammation in asthmatics through activation of A2B adenosine receptor (A2BAdoR). Selective antagonists have been shown to attenuate airway reactivity and improve inflammatory conditions in pre-clinical studies. Hence, the identification of novel, potent and selective A2BAdoR antagonist may be beneficial for the potential treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). Towards this effort, we explored several prop-2-ynylated C8-aryl or heteroaryl substitutions on xanthine chemotype and found that 1-prop-2-ynyl-1H-pyrazol-4-yl moiety was better tolerated at the C8 position. Compound 59, exhibited binding affinity (Ki) of 62 nM but was non-selective for A2BAdoR over other AdoRs. Incorporation of substituted phenyl on the terminal acetylene increased the binding affinity (Ki) significantly to <10 nM. Various substitutions on terminal phenyl group and different alkyl substitutions on N-1 and N-3 were explored to improve the potency, selectivity for A2BAdoR and the solubility. In general, compounds with meta-substituted phenyl provided better selectivity for A2BAdoR compared to that of para-substituted analogs. Substitutions such as basic amines like pyrrolidine, piperidine, piperazine or cycloalkyls with polar group were tried on terminal acetylene, keeping in mind the poor solubility of xanthine analogs in general. However, these substitutions led to a decrease in affinity compared to compound 59. Subsequent SAR optimization resulted in identification of compound 46 with high human A2BAdoR affinity (Ki = 13 nM), selectivity against other AdoR subtypes and with good pharmacokinetic properties. It was found to be a potent functional A2BAdoR antagonist with a Ki of 8 nM in cAMP assay in hA2B-HEK293 cells and an IC50 of 107 nM in IL6 assay in NIH-3T3 cells. Docking study was performed to rationalize the observed affinity data. Structure-activity relationship (SAR) studies also led to identification of compound 36 as a potent A2BAdoR antagonist with Ki of 1.8 nM in cAMP assay and good aqueous solubility of 529 µM at neutral pH. Compound 46 was further tested for in vivo efficacy and found to be efficacious in ovalbumin-induced allergic asthma model in mice.
Asunto(s)
Antagonistas del Receptor de Adenosina A2/química , Antagonistas del Receptor de Adenosina A2/uso terapéutico , Asma/tratamiento farmacológico , Receptor de Adenosina A2B/metabolismo , Xantina/química , Xantina/uso terapéutico , Antagonistas del Receptor de Adenosina A2/metabolismo , Antagonistas del Receptor de Adenosina A2/farmacocinética , Animales , Asma/inducido químicamente , Asma/metabolismo , Perros , Diseño de Fármacos , Células Hep G2 , Humanos , Células de Riñón Canino Madin Darby , Ratones , Ratones Endogámicos C57BL , Microsomas Hepáticos/metabolismo , Simulación del Acoplamiento Molecular , Ovalbúmina , Ratas , Receptor de Adenosina A2B/química , Xantina/metabolismo , Xantina/farmacocinéticaRESUMEN
This report describes the synthesis of [11C]2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone ([11C]FR194921), a highly selective, nonxanthine-type adenosine A(1) receptor antagonist, used in brain imaging in rats and conscious monkeys as a potential novel PET tracer. [11C]FR194921 was successfully synthesized in 19 min after [11C]CH3I formation. The radiochemical yield was 38+/-3%; and radioactivity was 4.1+/-0.4 GBq, calculated from end of synthesis; radiochemical purity was higher than 99%; and the specific radioactivity was 25.0+/-8.1 GBq micromol(-1) (n=5). In a rat experiment, the distribution of [11C]FR194921 was higher in the hippocampus, striatum and cerebellum regions. This accumulation was significantly decreased by approximately 50% by pretreatment with 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), an adenosine A1 receptor antagonist, which indicated specific binding of the radioligand to adenosine A1 receptors. In conscious monkey PET experiments, [11C]FR194921 accumulated in several regions of the brain, especially in the occipital cortex, thalamus and striatum. These results suggest that [11C]FR194921 can be used as an agent for imaging adenosine A1 receptors in vivo by positron emission tomography (PET).
Asunto(s)
Encéfalo/diagnóstico por imagen , Encéfalo/metabolismo , Piperidinas/farmacocinética , Tomografía de Emisión de Positrones/métodos , Piridazinas/farmacocinética , Receptor de Adenosina A1/metabolismo , Antagonistas del Receptor de Adenosina A1 , Animales , Radioisótopos de Carbono/química , Radioisótopos de Carbono/farmacocinética , Masculino , Tasa de Depuración Metabólica , Especificidad de Órganos , Piperidinas/química , Piridazinas/química , Radiofármacos/síntesis química , Radiofármacos/farmacocinética , Ratas , Ratas Sprague-Dawley , Coloración y Etiquetado/métodos , Distribución Tisular , Imagen de Cuerpo Entero/métodos , Xantina/farmacocinéticaRESUMEN
Transmitters and cotransmitters of the sympathetic nervous system are involved in the regulation of a variety of immune cell functions. However, it is not entirely clear what stimuli lead to the release of these molecules in immune organs. In this study, we investigated whether local ischemia can cause the parallel release of norepinephrine and its cotransmitter, ATP, in the spleen. Ischemic-like conditions, simulated by transient (15 min) O(2) and glucose deprivation, elicited a reversible increase in the release of both norepinephrine and purines from superfused spleen strips preloaded with [3H]norepinephrine or [3H]adenosine. HPLC analysis of the released tritium label revealed a net increase in the amount of ATP, ADP, AMP, adenosine, inosine, hypoxanthine and xanthine in response to ischemic-like condition. Selective O(2) or glucose deprivation, and Ca(2+)-free conditions differentially affected the outflow of [3H]norepinephrine and [3H]purines, indicating that they derived from different sources. The ABC transporter inhibitors glibenclamide (100 microM) and verapamil (100 microM) as well as low-temperature inhibited [3H]purine release evoked by ischemic-like conditions. Surgical denervation of the spleen reduced endogenous catecholamine content and [3H]norepinephrine uptake of the spleen, but not that of [3H]adenosine. In summary, these results demonstrate the release of norepinephrine and purines in response to an ischemic-like condition in an immune organ. Although both could provide an important source of extracellular catecholamines and purines involved at various levels of immunomodulation, the source and mechanism of norepinephrine and purine efflux seem different.
Asunto(s)
Adenosina/farmacocinética , Isquemia/inmunología , Isquemia/metabolismo , Norepinefrina/farmacocinética , Bazo/metabolismo , Simpatomiméticos/farmacocinética , Vasodilatadores/farmacocinética , Adenina/farmacocinética , Adenosina Difosfato/farmacocinética , Adenosina Monofosfato/farmacocinética , Adenosina Trifosfato/farmacocinética , Animales , Calcio/farmacología , Hipoxantina/farmacocinética , Inosina/farmacocinética , Masculino , Ratas , Ratas Wistar , Bazo/irrigación sanguínea , Bazo/inervación , Simpatectomía , Sistema Nervioso Simpático/efectos de los fármacos , Sistema Nervioso Simpático/inmunología , Sistema Nervioso Simpático/metabolismo , Tetrodotoxina/farmacología , Tritio , Xantina/farmacocinéticaRESUMEN
Monoclonal antibodies (mAbs) such as the tumor-specific anti-epidermal growth factor receptor variant III (EGFRvIII) that are internalized and degraded after cell binding necessitate the use of radioiodination methods that minimize the loss of radioactivity from the tumor cell after intracellular processing. The purpose of the current study was to determine the suitability of N-succinimidyl 4-guanidinomethyl-3-iodobenzoate (SGMIB) for labeling this internalizing mAb. A series of paired-label biodistribution experiments were performed in athymic mice bearing subcutaneous, EGFRvIII-expressing, D-256 human glioma and U87 Delta EGFR xenografts. The tissue distribution of radioiodine activity following injection of anti-EGFRvIII mAb L8A4 labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate (SGMIB) were compared to those for mAb labeled using Iodogen, N-succinimidyl 3-iodo-5-pyridinecarboxylate (SIPC) as well as the Boc-protected precursor of SGMIB. Tumor uptake of radioiodine activity for mAb labeled via SGMIB was significantly higher than co-administered L8A4 radioiodinated by other methods. For example, 3 days after injection, D-256 tumor uptake of L8A4 labeled via SGMIB was 20.4 +/- 4.6% ID/g compared with 11.7 +/- 5.5% ID/g when the SIPC method was used. Thyroid uptake for L8A4 (SGMIB) was up to 36 times lower than L8A4 (Iodogen) and less than 0.35% in all experiments, indicating a low degree of deiodination in vivo. These results suggest that SGMIB may be a useful reagent for the radioiodination of this internalizing anti-EGFRvIII mAb.
Asunto(s)
Receptores ErbB/metabolismo , Urea/análogos & derivados , Xantina/farmacocinética , Animales , Glioma/metabolismo , Humanos , Ratones , Ratones Endogámicos BALB C , Distribución Tisular , Trasplante Heterólogo , XantinasRESUMEN
We evaluated the potential of [(11)C]MPDX as a radioligand for mapping adenosine A(1) receptors in comparison with previously proposed [(11)C]KF15372 in cat brain by PET. Two tracers showed the same brain distribution. Brain uptake of [(11)C]MPDX (Ki = 4.2 nM) was much higher and washed out faster than that of [(11)C]KF15372 (Ki = 3.0 nM), and was blocked by carrier-loading or displaced with an A(1) antagonist. The regional A(1) receptor distribution evaluated with kinetic analysis is consistent with that previously measured in vitro. [(11)C]MPDX PET has a potential for mapping adenosine A(1) receptors in brain.
Asunto(s)
Encéfalo/diagnóstico por imagen , Diuréticos/farmacocinética , Receptores Purinérgicos P1/metabolismo , Xantina/farmacocinética , Xantinas/farmacocinética , Animales , Encéfalo/metabolismo , Gatos , Ensayo de Unión Radioligante , Distribución Tisular , Tomografía Computarizada de EmisiónRESUMEN
8-Cyclopentyl-3-[(E)-3-[(131)I]iodoprop-2-en-1-yl]-1-propylxanthine (2*) was generated by iododestannylation of the tributyl-stannyl-precursor with [(131)I]NaI and chloramine T. The radiochemical yield of 2* was 82 +/- 4%, and the purity exceeded 98%. The specific activity was 33 +/- 19 GBq/micromol. Affinities for rat, pig and human A(1) adenosine receptors (A(1)ARs) were in the low nanomolar range, but poor selectivity for the human A(1)AR over the A(2A)AR was found. Additionally, in vitro and ex vivo autoradiographic studies revealed high unspecific binding which makes this ligand unsuitable for SPECT imaging.
Asunto(s)
Encéfalo/diagnóstico por imagen , Encéfalo/metabolismo , Receptores Purinérgicos P1/metabolismo , Tomografía Computarizada de Emisión de Fotón Único/métodos , Xantina/farmacocinética , Animales , Autorradiografía , Línea Celular , Femenino , Humanos , Técnicas In Vitro , Masculino , Tasa de Depuración Metabólica , Ratones , Especificidad de Órganos , Antagonistas de Receptores Purinérgicos P1 , Radiofármacos/síntesis química , Radiofármacos/farmacocinética , Ratas , Ratas Wistar , Receptores Purinérgicos P1/clasificación , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Especificidad de la Especie , Porcinos , Distribución Tisular , Xantina/síntesis química , XantinasRESUMEN
This paper is a report from a pharmacoscintigraphic study with an Egalet constant-release system containing caffeine and natural abundance samarium oxide. First the formulation was tested in vitro to clarify integrity during irradiation in the nuclear reactor. Then six healthy male volunteers were enrolled into the in vivo study. The in vitro release of caffeine obeyed all the time linear zero-order kinetics. The in vivo release of radioactive Sm2O3 consisted of three consequent linear phases with different slopes. The release rate was fastest while the product was in the small intestine and slowest when the product was in the descending colon. In terms of the bioavailability of caffeine, the most important factor seemed to be the residence time in the ascending and transverse colon. A long residence time in these sections led to high AUC values for caffeine.
Asunto(s)
Preparaciones de Acción Retardada/administración & dosificación , Análisis de Activación de Neutrones/métodos , Cintigrafía/métodos , Adulto , Área Bajo la Curva , Disponibilidad Biológica , Cafeína/administración & dosificación , Cafeína/sangre , Cafeína/farmacocinética , Química Farmacéutica/instrumentación , Preparaciones de Acción Retardada/farmacocinética , Tracto Gastrointestinal/diagnóstico por imagen , Humanos , Masculino , Óxidos/administración & dosificación , Óxidos/farmacocinética , Radioisótopos , Samario/administración & dosificación , Samario/farmacocinética , Xantina/administración & dosificación , Xantina/sangre , Xantina/farmacocinéticaRESUMEN
In previous in vivo studies with mice, rats and cats, we have demonstrated that [11C]MPDX ([1-methyl-11C]8-dicyclopropylmethyl-1-methyl-3-propylxanthine) is a potential radioligand for mapping adenosine A1 receptors of the brain by positron emission tomography (PET). In the present study, we performed a preclinical study. The radiation absorbed-dose by [11C]MPDX in humans estimated from the tissue distribution in mice was low enough for clinical use, and the acute toxicity and mutagenicity of MPDX were not found. The monkey brain was clearly visualized by PET with [11C]MPDX. We have concluded that [11C]MPDX is suitable for mapping adenosine A1 receptors in the human brain by PET.
Asunto(s)
Encéfalo/diagnóstico por imagen , Encéfalo/metabolismo , Receptores Purinérgicos P1/metabolismo , Xantina/farmacocinética , Xantina/toxicidad , Xantinas , Animales , Relación Dosis-Respuesta a Droga , Relación Dosis-Respuesta en la Radiación , Evaluación Preclínica de Medicamentos , Femenino , Humanos , Macaca mulatta , Masculino , Ratones , Ratones Endogámicos , Pruebas de Mutagenicidad , Especificidad de Órganos , Dosis de Radiación , Radiometría , Radiofármacos/farmacocinética , Ratas , Sensibilidad y Especificidad , Especificidad de la Especie , Distribución Tisular , Tomografía Computarizada de Emisión , Pruebas de Toxicidad AgudaRESUMEN
Intraperitoneal administration of guanosine to rats with chronic spinal cord injury stimulates remyelination and functional recovery. If guanosine produced its effects in the nervous system, it should enter it and elevate endogenous concentrations. [(3)H]-guanosine (8 mg/kg) was administered intraperitoneally to rats and its distribution and concentration in different sites determined. Guanosine rapidly entered all tissues; its concentration peaked at about 15 minutes except in adipose tissue and CNS where it continued to rise for 30 minutes. Its chief metabolic product in all sites was guanine with over twice as much guanine as guanosine present in CNS after 30 minutes.